Abstract: Objective To investigate the effect of increase extent of serum CA19-9 and CA125 in predicting resectability of pancreatic ductal adenocarcinoma preoperatively. Methods From January 2009 to December 2015, the clinical data of 441 patients with pancreatic ductal adenocarcinoma who were diagnosed pathologically and were evaluated to be resectable by radiology in our hospital were retrospectively analyzed. Patients were divided into resectable group and non-resectable group according to R0 resection. Preoperative serologic tumor markers including CA 19-9 and CA 125 in 2 groups were analyzed. Results There was significant statistical difference in CA19-9 and CA125 between resectable group and non-resectable group (P< 0.001). After correction of CA19-9 in the patients with direct bilirubin higher than 34.2 μmol/L, significant statistical difference in CA19-9 between two groups was still present (P< 0.001). Logistics multiple regression analysis and ROC curve showed that CA19-9 (cut-off= 582.10 U /mL, and adjusted CA19-9 cut-off= 449.70 U/mL) and CA125 (cut-off= 41.45 U/mL) were selected as predicting markers in resectability of pancreatic ductal adenocarcinoma. Conclusions Preoperative increase extent of CA19-9 and CA125 could assist to predict resectability of pancreatic ductal adenocarcinoma. The patients will have no chance of R0 resection when tumor markers increase more than cut-off value.

Key words: Pancreatic ductal adenocarcinoma, CA19-9, CA125, Resectability